132 related articles for article (PubMed ID: 28288473)
1. Expression Pattern of Smad4/GATA3 as a Predictor of Survival in Invasive Ductal Carcinoma of the Breast.
Min KW; Kim DH; Do SI; Chae SW; Kim K; Sohn JH; Lee HJ; Do IG; Pyo JS; Kim Y; Kim DH; Yang JH; Lee SJ; Oh YH; Oh S; Choi SH; Park YL; Park CH; Kim EK; Kwon MJ; Seo J
Pathobiology; 2017; 84(3):130-138. PubMed ID: 28288473
[TBL] [Abstract][Full Text] [Related]
2. Negative association between GATA3 and fascin could predict relapse-free and overall survival in patients with breast cancer.
Min KW; Kim DH; Do SI; Chae SW; Kim K; Sohn JH; Pyo JS; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kim EK; Kwon MJ; Seo J; Moon KM
Virchows Arch; 2016 Apr; 468(4):409-16. PubMed ID: 26719157
[TBL] [Abstract][Full Text] [Related]
3. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
[TBL] [Abstract][Full Text] [Related]
4. GATA3 transcription factor abrogates Smad4 transcription factor-mediated fascin overexpression, invadopodium formation, and breast cancer cell invasion.
Sun J; He H; Pillai S; Xiong Y; Challa S; Xu L; Chellappan S; Yang S
J Biol Chem; 2013 Dec; 288(52):36971-82. PubMed ID: 24235142
[TBL] [Abstract][Full Text] [Related]
5. Higher levels of GATA3 predict better survival in women with breast cancer.
Yoon NK; Maresh EL; Shen D; Elshimali Y; Apple S; Horvath S; Mah V; Bose S; Chia D; Chang HR; Goodglick L
Hum Pathol; 2010 Dec; 41(12):1794-801. PubMed ID: 21078439
[TBL] [Abstract][Full Text] [Related]
6. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.
McCleskey BC; Penedo TL; Zhang K; Hameed O; Siegal GP; Wei S
Am J Clin Pathol; 2015 Nov; 144(5):756-63. PubMed ID: 26486740
[TBL] [Abstract][Full Text] [Related]
7. Smad4/Fascin index is highly prognostic in patients with diffuse type EBV-associated gastric cancer.
Son BK; Kim DH; Min KW; Kim EK; Kwon MJ
Pathol Res Pract; 2018 Apr; 214(4):475-481. PubMed ID: 29572117
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
Demir H; Turna H; Can G; Ilvan S
J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
[TBL] [Abstract][Full Text] [Related]
9. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
[TBL] [Abstract][Full Text] [Related]
10. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
11. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma.
El-Gendi SM; Mostafa MF
Pathol Oncol Res; 2016 Jul; 22(3):461-70. PubMed ID: 26597806
[TBL] [Abstract][Full Text] [Related]
12. SMAD4 is a potential prognostic marker in human breast carcinomas.
Liu NN; Xi Y; Callaghan MU; Fribley A; Moore-Smith L; Zimmerman JW; Pasche B; Zeng Q; Li YL
Tumour Biol; 2014 Jan; 35(1):641-50. PubMed ID: 23975369
[TBL] [Abstract][Full Text] [Related]
13. The impact of the effectiveness of GATA3 as a prognostic factor in breast cancer.
Fararjeh AS; Tu SH; Chen LC; Liu YR; Lin YK; Chang HL; Chang HW; Wu CH; Hwang-Verslues WW; Ho YS
Hum Pathol; 2018 Oct; 80():219-230. PubMed ID: 29902578
[TBL] [Abstract][Full Text] [Related]
14. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
15. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and clinicopathological value of GATA binding protein 3 in breast cancer: A systematic review and meta-analysis.
Guo Y; Yu P; Liu Z; Maimaiti Y; Chen C; Zhang Y; Yin X; Wang S; Liu C; Huang T
PLoS One; 2017; 12(4):e0174843. PubMed ID: 28394898
[TBL] [Abstract][Full Text] [Related]
17. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups.
Ni YB; Tsang JY; Chan SK; Tse GM
Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335
[TBL] [Abstract][Full Text] [Related]
18. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
19. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
Wendroth SM; Mentrikoski MJ; Wick MR
Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
[TBL] [Abstract][Full Text] [Related]
20. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
Mehra R; Varambally S; Ding L; Shen R; Sabel MS; Ghosh D; Chinnaiyan AM; Kleer CG
Cancer Res; 2005 Dec; 65(24):11259-64. PubMed ID: 16357129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
